CAI · Caris Life Sciences, Inc.

Caris Life Sciences has executed a significant refinancing transaction that substantially increases its available credit capacity while extending debt maturities. The new $1.2 billion credit facility structure provides immediate liquidity through the $400 million initial term loan, strategic acquisition funding through the $300 million delayed draw facility, and future flexibility with the $500 million incremental facility. By refinancing its previous January 2023 credit agreement, the company has likely improved its debt terms and extended its maturity profile, with the initial term loan now maturing in April 2031. The interest rate structure (Term SOFR +5.00% or Base Rate +4.00%) represents the company's current borrowing costs, while the $50 million minimum cash covenant provides lenders with protection while allowing operational flexibility. The restriction of the delayed draw facility to 'Permitted Acquisitions' signals management's intent to pursue strategic growth through acquisitions, with the August 2027 availability window establishing a timeline for such transactions. The comprehensive security package, covering substantially all company assets, represents standard practice for leveraged credit facilities of this nature.